TL;DR for clinics, marcas de bienestar, and patients
- Small controlled studies suggest that some photobiomodulation (Pbm) protocols can temporarily increase local skin or capillary blood-flow measurements.
- The finding is narrow. It does not automatically mean higher blood flow in a larger artery, better whole-body circulation, improved tissue oxygen, or a lasting clinical benefit.
- Results vary by wavelength, optical dose, área de tratamiento, método de medición, temperature, and individual response. Positive and negative human findings both exist.
- Nitric oxide is one plausible contributor to vasodilation, but the light-sensitive pathway is not settled and should not be presented as a proven one-step mechanism.
- An exact device can have a cleared indication for temporarily increasing local blood circulation, but that wording does not transfer to another product and does not establish treatment for chronic poor circulation, peripheral artery disease (PAD), diabetic vascular disease, or cardiovascular disease.
- People with reduced protective sensation or wounds need exact-device safety review, while new vascular warning signs require medical assessment rather than self-treatment.
nota medica: This article is educational and does not diagnose or treat a vascular condition. Recurrent leg pain during activity, one foot becoming colder than the other, numbness, color change, rest pain, or a slow-healing wound can require medical assessment; el A NOSOTROS. National Heart, Lung, and Blood Institute (NHLBI) lists these among possible PAD symptoms. The NHLBI’s living-with-PAD guidance advises emergency care for a sudden loss of feeling or movement in a foot, especially when it becomes blue or pale and colder than the other foot. Do not delay professional care to try a light device.
¿La terapia con luz roja aumenta el flujo sanguíneo??
Sometimes—but only in a limited, local, and protocol-specific sense.
Several small human studies have recorded a short-term increase in skin perfusion, capillary blood-cell velocity, or another local microcirculatory measure after a specific PBM exposure. Other studies found no change in larger-vessel measurements, plasma nitrite, transcutaneous oxygen, or related outcomes.
The most accurate answer is therefore not a universal “yes” or “no.” It is:
Some red or near-infrared protocols have changed local microcirculation measurements in small human studies. Those results do not establish sustained systemic circulation improvement or treatment of a vascular disease.
That distinction matters for clinics because a patient may hear “increased blood flow” as “this will treat the cause of my cold feet, leg pain, ulcer, or PAD.” The studies do not support that leap.
“Blood Flow” Is Not One Outcome
A result at one level cannot substitute for evidence at another.
| Evidence level | Example measurement | What it can show | What it cannot establish by itself |
|---|---|---|---|
| Local skin or capillary microcirculation | Laser Doppler flow, photoplethysmography, capillary blood-cell velocity | A short-term change in a small illuminated area | Larger-artery flow, whole-body circulation, or disease improvement |
| Local tissue oxygen | Transcutaneous oxygen pressure (TcPO₂) | Oxygen measured through the skin at a defined site | The cause of any change or a durable wound-healing benefit |
| Larger-vessel hemodynamics | Femoral artery velocity or pulsatility | A vascular measurement in a named artery | Skin-capillary response, total limb perfusion, or clinical benefit |
| Systemic markers | Plasma nitrite, blood pressure, endothelial-function tests | A selected body-wide or vascular marker | Symptom relief or disease modification unless the trial measures it |
| Patient and disease outcomes | Walking distance, curación de heridas, dolor, hospitalization, limb events | A clinically relevant result in a defined patient group | Transferability to another diagnosis, dispositivo, or protocol |
“Circulation” is useful everyday language, but it is too broad to serve as a scientific endpoint. Before repeating a claim, ask: What was measured, dónde, for how long, in whom, and with which device parameters?
The instruments are not interchangeable. In the Riaz laser-Doppler study, perfusion was reported in relative blood-perfusion units rather than an absolute flow such as milliliters per minute; el Gavish study also used photoplethysmography, which records an optical pulse-related signal rather than direct volumetric flow. A within-study change can therefore be informative, but percentages from different instruments, settings, and body sites should not be pooled as though they measured the same quantity.
What Did Controlled Human Studies Find?
The human evidence contains local positive signals, null results, and substantial limits.
| Study | Population and protocol | Measurement | Main finding | Lo que no prueba |
|---|---|---|---|---|
| Mak and Cheing, 2012 | 30 healthy adults; randomized to 890 nm monochromatic infrared energy, sham, or a warm pack on the foot for 30 minutos | Capillary blood-cell velocity and superficial skin flux | The active group showed greater increases than sham and heat | Long-term benefit, systemic circulation, or an effect in PAD |
| Gavish et al., 2020 | 20 healthy nonsmokers; randomized to 633 nm red or 830 nm near-infrared at the wrist for 5 minutos | Photoplethysmography, laser Doppler, and skin temperature | El 830 nm group showed a median microcirculatory increase during and after exposure; el 633 nm group did not show a median increase | A sham-controlled treatment effect; each wavelength group had only about 10 people, and responders varied |
| Dutra et al., 2021 | 13 healthy untrained men; aleatorio, doble ciego, sham-controlled crossover using combined 630/850 nm PBM before cycling | Femoral peak systolic velocity, pulsatility index, plasma nitrite, and exercise performance | No significant differences in the vascular measures, nitrite, or performance | That every local skin response is absent; the study addressed a different protocol and endpoint |
| Franzen-Korzendorfer et al., 2008 | 18 people with diabetes and loss of protective sensation; one foot received 890 nm active exposure and the other sham over 11–12 sessions | TcPO₂, sensation, and pain | No significant active-versus-sham difference in the three outcomes | A final verdict for all diabetic-foot or vascular protocols; allocation was quasi-random and the sample was small |
| Riaz et al., 2026 | 24 healthy adults; 890 nm near-infrared after a same-person placebo condition | Local laser-Doppler skin flow and temperature | Local flow increased after some continuous or intermittent exposures, with large individual variation | A randomized effect independent of heat; placebo always came first, continuous exposure raised skin temperature by about 6°C, and small heat controls were not inferentially tested |
These studies measured different body sites and vascular levels and used different wavelengths, power densities, exposure times, temperatures, and outcomes. Most enrolled healthy adults and assessed the response during exposure, immediately afterward, or within a short same-session follow-up. They do not establish next-day persistence or a cumulative effect.
These studies do not establish a wavelength hierarchy. Among the studies reviewed here, only Gavish and colleagues directly compared red with near-infrared light: in that small, no-sham study, el 830 nm group showed a median local microcirculatory increase while the 633 nm group did not. One active-wavelength comparison cannot establish a general advantage for near-infrared light.
Commercial context: Commercial involvement does not by itself validate or invalidate a result, but it belongs in the interpretation. In the Gavish study, one author’s listed affiliation was a commercial company; the accessible record did not include a separate conflict-of-interest declaration. For the Franzen-Korzendorfer study, Anodyne Therapy donated the active and sham devices, and the first author was a manager at American Medical Technologies. These facts sit alongside each study’s design strengths and limitations.
Why Do Study Results Differ?
A PBM result belongs to the complete exposure and measurement setup—not to the wavelength label alone.
Important sources of variation include:
- Vascular level and body site. Skin perfusion at the wrist or foot is not the same measurement as femoral artery velocity or total limb blood flow.
- Wavelength and spectral output. “Red light” can refer to different visible-red bands, while near-infrared protocols may use 810, 830, 850, 890 Nuevo Méjico, or another band.
- Irradiance and radiant exposure. Potencia por área, tiempo de sesión, distancia, beam area, ciclo de trabajo, and pulse pattern all affect the delivered exposure.
- Temperature. Warming the skin can itself change local perfusion. A study needs suitable controls and temperature records before attributing the whole response to a nonthermal photochemical pathway.
- Momento. A change recorded during exposure or 20 minutes later does not establish a persistent effect across days or months.
- Participant characteristics. Edad, baseline vascular tone, smoking, medicamento, diabetes, PAD, neuropathy, and other conditions can change both the response and the risk.
- Study design. Small samples, fixed treatment order, absent sham controls, multiple uncorrected comparisons, and selective reporting can make an apparent effect less certain.
For device teams, the practical implication is simple: a study using one wavelength cannot validate a product merely because the product catalog lists the same nominal wavelength. The exact output, geometry, área de tratamiento, schedule, intended user, comparator, and endpoint still need to match.
Does Nitric Oxide Explain the Blood-Flow Response?
Nitric oxide is a plausible contributor, but the PBM pathway is not settled.
Nitric oxide helps regulate vascular tone, so researchers have investigated whether red or near-infrared light can make biologically stored nitric oxide more available. In laboratory work, Keszler et al. found wavelength-dependent release from S-nitrosothiols and dinitrosyl iron complexes and observed relaxation in isolated mouse facial arteries.
That supports biological plausibility. It does not prove that a consumer device releases a clinically important amount of nitric oxide in a person or that nitric oxide explains every local perfusion result.
Citocromo c oxidasa (director de operaciones) is also frequently presented as the established PBM photoacceptor that releases inhibitory nitric oxide. The evidence is less settled than that marketing shorthand suggests. A 2020 critical review questioned whether reliable, reproducible evidence was sufficient to assign CCO that central role. A later isolated-enzyme experiment descubrió que 670 o 830 nm light did not change CCO oxygen consumption or reverse inhibition from a nitric-oxide donor under the tested conditions.
The responsible clinic explanation is:
PBM may influence vascular signaling through more than one light-sensitive or secondary pathway, and nitric oxide may contribute. The exact human pathway and its clinical importance remain under investigation.
Does This Evidence Apply to Poor Circulation, PAD, or Diabetic Foot?
No direct treatment conclusion can be made from the current evidence.
“Poor circulation” is a symptom description, not one diagnosis. Arterial disease, venous disease, neuropathy, medication effects, temperature regulation, and other conditions can produce different complaints and require different evaluation.
The closest patient evidence remains small and uses outcomes that do not directly answer the circulation question:
- A 2022 aleatorio, double-blind pilot in 20 people studied at-home 808 nm PBM plus standard care in people with severe diabetic foot ulcers and neuropathy; 18 also had PAD, and major comorbidities were common. Wound-area reduction favored active PBM, but the trial did not establish that improved perfusion caused the result. The manufacturer supplied the active and sham devices, paid for third-party caregiving and statistical services, and provided the study camera; one author disclosed paid consulting for the manufacturer. Those relationships do not by themselves invalidate the result, but they add context to a small pilot.
- A 2025 pilot in 11 people with diabetic foot ulcer and PAD compared PBM plus exercise with exercise alone. Some measures improved from baseline, but no significant between-group differences were found. The sample and allocation method make it feasibility evidence, not a treatment conclusion.
- A 2026 systematic review of six randomized LED trials reported possible signals for wound area, wound-bed quality, or microcirculation in chronic lower-limb wounds. Protocols were highly heterogeneous, no quantitative meta-analysis was possible, and the overall GRADE certainty was very low.
Wound healing and blood flow are related clinical topics, but they are not interchangeable endpoints. A smaller wound does not by itself prove that PBM improved arterial perfusion; a local perfusion reading does not establish wound healing; and neither establishes treatment for PAD.
This does not prove that PBM has no role in future vascular or wound-care research. It means the present evidence is insufficient for a consumer-device treatment claim or for replacing established medical evaluation and care.
What Are the Safety Boundaries for Circulation-Related Use?
A research exposure is not a home-use instruction, and safety depends on the exact device and user.
In the Riaz study, one continuous 890 nm exposure condition raised local skin temperature by about 6°C in healthy adults. That is a protocol-specific observation and a possible thermal contributor to the measured flow change—not evidence that every PBM device heats the skin by 6°C. It does show why clinics should verify temperature behavior instead of assuming that every red or near-infrared mode is nonthermal.
Reduced protective sensation changes the risk-control question because a user may be less able to notice uncomfortable heating. For a person with diabetic neuropathy, an active or slow-healing wound, known vascular disease, or another condition affecting the treated area, use should be evaluated against the exact device’s instrucciones, contraindicaciones, advertencias, temperature behavior, session limits, and supervision requirements. No universal temperature limit or treatment dose can be derived from the studies reviewed here.
Do not use a wellness light program to self-manage a newly cold, pale, or blue foot, sudden loss of feeling or movement, rest pain, or a worsening or slow-healing wound. Those findings need medical assessment. This article also does not create a universal PBM contraindication list: medication-related photosensitivity and other condition-specific restrictions must be checked against the product’s labeling and qualified clinical advice.
What Can Clinics Say Without Overstating the Evidence?
Describe the measured finding and the limit in the same sentence.
| Evidence-matched language | Overstatement to avoid |
|---|---|
| “Some small human studies found temporary increases in local skin or capillary blood-flow measurements after specific PBM protocols.” | “Red light therapy improves circulation.” |
| “In one small active-wavelength comparison without a sham group, 830 nm showed a median local microcirculatory increase while 633 nm did not; this does not establish a general wavelength advantage.” | “Near-infrared is proven to increase blood flow better than red light.” |
| “Nitric oxide is one proposed contributor to PBM-related vasodilation; the pathway is still being studied.” | “Red light releases nitric oxide, opens blood vessels, and restores circulation.” |
| “Local microcirculation is not the same endpoint as larger-artery flow or disease improvement.” | “Better skin perfusion means better cardiovascular health.” |
| “Current evidence does not establish treatment for PAD or another vascular disease.” | “Helps poor circulation in the legs and feet.” |
| For an exact device with matching U.S. clearance and labeling: “temporarily increase local blood circulation where applied.” | “Our device can improve circulation because another product with a similar wavelength has FDA clearance.” |
| “This exact model received 510(k) clearance for the Indications for Use stated in its FDA record.” | “FDA approved or endorsed this device—or its proposed circulation mechanism.” |
Permitted wording depends on the exact product, uso previsto, mercado objetivo, audience, evidence, etiqueta, and overall consumer impression. For the broader review workflow, él está en Wakelife's Guía de reclamaciones de dispositivos de belleza LED. It separates a measured product fact from a beauty, bienestar, therapeutic, or medical claim; it is not a substitute for market-specific legal or regulatory review.
Can “Temporarily Increase Local Blood Circulation” Appear in FDA-Cleared Indications?
Yes for some exact devices in the United States—not for PBM as a generic category.
Por ejemplo, la FDA K240222 510(k) summary for specified Dermalux LED devices includes, for the 830 nm near-infrared mode, wording about temporarily increasing local blood circulation where applied. That indication is tied to the named devices, their intended use, technological comparison, and cleared labeling. It does not authorize another 830 nm product to copy the claim, and it does not establish treatment for PAD or chronic poor circulation.
An earlier device record shows a different regulatory frame. El 2006 K060792 clearance letter and attachments list one regulation number—21 CFR 890.5500, regulation name Infrared lamp—and both product codes ILY and GEX. The applicant’s 510(k) summary separately lists 21 CFR 878.4810 y 890.5500. Within that summary, the named 660/940 nm red and near-infrared configurations carry the heat, topical-heating, tissue-temperature, and circulation wording, while the blue-light functions carry the acne indication. FDA’s separate ILY product-classification record describes the device type as lamp, infrared, therapeutic heating, places it in Physical Medicine, and links FDA guidance for heating and cooling device 510(k) applications. This does no mean that every PBM circulation claim is thermal. It shows that K060792 cannot be cited as FDA recognition of a nonthermal nitric-oxide mechanism.
K060792 also illustrates why claim teams should use the exact device’s formal Indications for Use and current labeling rather than copying a sentence from an applicant’s 510(k) summary. The summary uses local blood circulation and states that the submitter considered the device suitable for prescription and non-prescription use. The enclosed Indications for Use omits local and marks Prescription Use. This historical contrast does not make every circulation-related device prescription-only. FDA’s current records list ILY as a Class II, 510(K) Exempt submission type and GEX as Class II with submission type 510(k); both records say GMP Exempt? No. The ILY exemption is subject to 21 CFR 890.9, including limits involving a different intended use or different fundamental scientific technology. Current 21 CFR 890.5500, product-code requirements, uso previsto, and Rx/OTC status must therefore be checked for any new device.
Research wording and regulatory wording answer different questions. A study can measure a local physiological change without authorizing a product claim. En cambio, a device-specific cleared indication does not prove that every product using a similar wavelength produces the same result.
The wording used to describe clearance also matters. FDA’s K060792 letter says its substantial-equivalence determination does not mean FDA determined that the device complies with other requirements of the Federal Food, Drug, and Cosmetic Act or with statutes and regulations administered by other federal agencies. Separately, 21 CFR 807.97 provides that submitting a premarket notification and subsequently receiving a substantial-equivalence determination does not denote official approval; creating an approval impression because of premarket-notification compliance is misleading and constitutes misbranding. Use accurate 510(k) clearance and exact Indications for Use language; do not convert it into FDA approved, FDA endorsement, or FDA recognition of a proposed mechanism. The same historical letter also points to registration and listing, etiquetado, sistema de calidad, and applicable radiation-control obligations; current requirements must be verified separately.
In the European Union, el Regulación de dispositivos médicos defines intended purpose through the manufacturer’s label, instructions for use, promotional or sales materials and statements, and clinical evaluation. Classification rules are then applied according to that intended purpose. A clinic or private-label brand should therefore map each circulation-related statement to the exact device documentation, uso previsto, mercado, and conformity route rather than borrowing language from an unrelated clearance.
How Should a Clinic Evaluate a Device for a Circulation-Related Wellness Program?
Start with the clinical and communication scope, then work backward to the device.
- Define the intended use. Is the program describing a general wellness routine, measuring a local physiological response, supporting recovery, or proposing to address a diagnosed condition? Those are not equivalent scopes.
- Name the target population. Healthy adults are not interchangeable with older adults, people with diabetes, people taking vasoactive medication, or patients with known vascular disease.
- Choose the endpoint. Decide whether the evidence question concerns local skin perfusion, tissue oxygen, an arterial measure, a symptom, walking performance, or a clinical outcome.
- Match the complete protocol. Compare wavelength, ancho de banda espectral, irradiancia, exposición radiante, distancia, tiempo de sesión, área de tratamiento, modo de pulso, temperature, schedule, and follow-up—not wavelength alone.
- Separate research evidence from exact-device evidence. A published study can support a scientific rationale. It does not automatically validate another model. Request mode-specific spectral and irradiance records, measurement conditions, sample identity, safety reports, and batch-control criteria. Wakelife IEC 62471, longitud de onda, and irradiance guide explains these evidence layers.
- Align every patient-facing statement. The website, consent material, handout, staff script, testimonial, instrucciones, advertencias, and follow-up process should remain within the same intended-use and evidence boundary.
- Build a referral boundary. A wellness device should not delay vascular assessment for symptoms or wounds that may require diagnosis and treatment.
How We Reviewed the Evidence
This is a focused evidence summary, not a systematic review. The search and source check were updated through July 29, 2026. We prioritized controlled human studies that directly measured local perfusion, tissue oxygen, a named artery, or another vascular endpoint, and we retained both positive and null findings. Laboratory mechanism studies were used only to explain biological plausibility. PAD and wound studies were used to define the boundary between a circulation measurement and a disease outcome, not to create treatment recommendations.
For the included sources, we checked article identifiers, accessible abstracts or full text, study design, relevant endpoints, and funding or conflict disclosures where available. Fabricante, detallista, and general commercial pages were not treated as clinical evidence. New evidence or corrections may change this summary, so the source set should be rechecked before a major claims or product-positioning decision.
La conclusión
Human research provides a credible but narrow signal: some PBM protocols can temporarily increase local skin or capillary blood-flow measurements. The evidence base is small, heterogeneous, and sensitive to protocol, temperature, measurement site, and individual response. It does not establish that one wavelength is generally superior.
The same research does no establish sustained whole-body circulation improvement, a reliable nitric-oxide mechanism in humans, or treatment for chronic poor circulation, PAD, diabetic vascular disease, or cardiovascular disease.
For clinics and wellness brands, the safest and most useful question is not “Does red light improve circulation?" Es:
Which population, device protocol, anatomical site, measurement, time window, and intended claim does the evidence actually support?
Evaluating a PBM device for a clinic or regulated wellness program? Start by defining the intended use, target population, and evidence endpoint. Wakelife can then help map device specifications and available documentation to that scope.
Referencias
- Mak MC, Cheing GL. Immediate effects of monochromatic infrared energy on microcirculation in healthy subjects. Fotomedicina y Cirugía Láser. 2012;30(4):193–199. doi:10.1089/pho.2011.3012.
- Gavish L, Hoffer O, Rabin N, et al. Microcirculatory response to photobiomodulation—why some respond and others do not. Láseres en Cirugía y Medicina. 2020;52(9):863–872. doi:10.1002/lsm.23225. Trial registration: NCT03357523.
- Dutra YM, Claus GM, Malta ES, et al. Fotobiomodulación 30 min or 6 h prior to cycling does not alter resting blood flow velocity, exercise-induced physiological responses or time to exhaustion in healthy men. Frontiers in Physiology. 2021;11:607302. doi:10.3389/fphys.2020.607302.
- Franzen-Korzendorfer H, Blackinton M, Rone-Adams S, McCulloch J. The effect of monochromatic infrared energy on transcutaneous oxygen measurements and protective sensation. Ostomy Wound Management. 2008;54(6):16–31.
- Riaz M, Bösch PC, Åm MK, et al. Effects of near-infrared photobiomodulation on local skin blood flow in healthy subjects. Photonics. 2026;13(2):119. doi:10.3390/photonics13020119.
- Keszler A, Lindemer B, Hogg N, Weihrauch D, Lohr NL. Wavelength-dependence of vasodilation and NO release from S-nitrosothiols and dinitrosyl iron complexes by far red/near infrared light. Archives of Biochemistry and Biophysics. 2018;649:47–52. doi:10.1016/j.abb.2018.05.006.
- Quirk BJ, Whelan HT. What lies at the heart of photobiomodulation: luz, citocromo c oxidasa, and nitric oxide—review of the evidence. Fotobiomodulación, Fotomedicina, y Cirugía Láser. 2020;38(9):527–530. doi:10.1089/photob.2020.4905.
- Quirk BJ, Whelan HT. Effect of red-to-near infrared light and a nitric oxide donor on the oxygen consumption of isolated cytochrome c oxidase. Fotobiomodulación, Fotomedicina, y Cirugía Láser. 2021;39(7):463–470. doi:10.1089/photob.2020.4978.
- Haze A, Gavish L, Elishoov O, et al. Treatment of diabetic foot ulcers in a frail population with severe co-morbidities using at-home photobiomodulation laser therapy. Láseres en la ciencia médica. 2022;37(2):919–928. doi:10.1007/s10103-021-03335-9.
- Chen SZ, Takahashi T, Lai HJ, Su HH, Cheng YJ. Therapeutic effects of photobiomodulation combined with exercise on patients with peripheral artery disease plus diabetic foot ulcer. Vida. 2025;15(9):1391. doi:10.3390/life15091391.
- Miranda MB, Barros ACS, de Paula AVL, et al. Clinical dosimetry and efficacy of LED photobiomodulation for chronic lower-limb wound healing. Láseres en la ciencia médica. 2026;41(1):117. doi:10.1007/s10103-026-04928-y.
- National Heart, Lung, and Blood Institute. Peripheral artery disease: symptoms. Consultado en julio. 28, 2026.
- National Heart, Lung, and Blood Institute. Peripheral artery disease: living with. Consultado en julio. 28, 2026.
- A NOSOTROS. Administración de Alimentos y Medicamentos. 510(k) summary: Dermalux Tri-Wave MD MKII and Dermalux Compact MD, K240222. 2024. Consultado en julio. 29, 2026.
- European Parliament and Council. Regulation (UE) 2017/745 en dispositivos médicos. Official Journal of the European Union. 2017. Consultado en julio. 29, 2026.
- A NOSOTROS. Administración de Alimentos y Medicamentos. 510(k) summary, substantial-equivalence letter, and Indications for Use: illumiMed, K060792. 2006. Consultado en julio. 29, 2026.
- Office of the Federal Register, National Archives and Records Administration. 21 CFR 890.5500: Infrared lamp. eCFR. Consultado en julio. 29, 2026. Annual-edition backup: GovInfo 2025.
- Office of the Federal Register, National Archives and Records Administration. 21 CFR 807.97: Misbranding by reference to premarket notification. eCFR. Consultado en julio. 29, 2026. Annual-edition backup: GovInfo 2025.
- A NOSOTROS. Administración de Alimentos y Medicamentos. Product Classification database entries for ILY: lamp, infrarrojo, therapeutic heating y GEX: powered laser surgical instrument. Consultado en julio. 29, 2026.
- Office of the Federal Register, National Archives and Records Administration. 21 CFR 890.9: Limitations of exemptions from section 510(k). eCFR. Consultado en julio. 29, 2026. Annual-edition backup: GovInfo 2025, Parte 890.
